Literature DB >> 24843148

Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections.

Peter Ankomah1, Bruce R Levin2.   

Abstract

The successful treatment of bacterial infections is the product of a collaboration between antibiotics and the host's immune defenses. Nevertheless, in the design of antibiotic treatment regimens, few studies have explored the combined action of antibiotics and the immune response to clearing infections. Here, we use mathematical models to examine the collective contribution of antibiotics and the immune response to the treatment of acute, self-limiting bacterial infections. Our models incorporate the pharmacokinetics and pharmacodynamics of the antibiotics, the innate and adaptive immune responses, and the population and evolutionary dynamics of the target bacteria. We consider two extremes for the antibiotic-immune relationship: one in which the efficacy of the immune response in clearing infections is directly proportional to the density of the pathogen; the other in which its action is largely independent of this density. We explore the effect of antibiotic dose, dosing frequency, and term of treatment on the time before clearance of the infection and the likelihood of antibiotic-resistant bacteria emerging and ascending. Our results suggest that, under most conditions, high dose, full-term therapy is more effective than more moderate dosing in promoting the clearance of the infection and decreasing the likelihood of emergence of antibiotic resistance. Our results also indicate that the clinical and evolutionary benefits of increasing antibiotic dose are not indefinite. We discuss the current status of data in support of and in opposition to the predictions of this study, consider those elements that require additional testing, and suggest how they can be tested.

Entities:  

Keywords:  immunology; population dynamics

Mesh:

Substances:

Year:  2014        PMID: 24843148      PMCID: PMC4060691          DOI: 10.1073/pnas.1400352111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  89 in total

1.  A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans.

Authors:  S Delacher; H Derendorf; U Hollenstein; M Brunner; C Joukhadar; S Hofmann; A Georgopoulos; H G Eichler; M Müller
Journal:  J Antimicrob Chemother       Date:  2000-11       Impact factor: 5.790

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

3.  Pharmacodynamic model to describe the concentration-dependent selection of cefotaxime-resistant Escherichia coli.

Authors:  Sara K Olofsson; Patricia Geli; Dan I Andersson; Otto Cars
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

Review 4.  Pharmacokinetics and pharmacodynamics of antimicrobials.

Authors:  G L Drusano
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

5.  Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa.

Authors:  Vincent H Tam; Amy N Schilling; Shadi Neshat; Keith Poole; David A Melnick; Elizabeth A Coyle
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

6.  Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Authors:  J Blaser; B B Stone; M C Groner; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

7.  Reducing antibiotic resistance.

Authors:  S J Schrag; V Perrot
Journal:  Nature       Date:  1996-05-09       Impact factor: 49.962

8.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Once-daily dosing in dogs optimizes daptomycin safety.

Authors:  F B Oleson; C L Berman; J B Kirkpatrick; K S Regan; J J Lai; F P Tally
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  Pharmacodynamics, population dynamics, and the evolution of persistence in Staphylococcus aureus.

Authors:  Paul J T Johnson; Bruce R Levin
Journal:  PLoS Genet       Date:  2013-01-03       Impact factor: 5.917

View more
  51 in total

Review 1.  Addressing Concerns about Changing the Route of Antimicrobial Administration from Intravenous to Oral in Adult Inpatients.

Authors:  Lizanne Béïque; Rosemary Zvonar
Journal:  Can J Hosp Pharm       Date:  2015 Jul-Aug

Review 2.  Antibiotic resistance: a primer and call to action.

Authors:  Rachel A Smith; Nkuchia M M'ikanatha; Andrew F Read
Journal:  Health Commun       Date:  2014-08-14

3.  Profile of Bruce Levin.

Authors:  Beth Azar
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-27       Impact factor: 11.205

Review 4.  Is selection relevant in the evolutionary emergence of drug resistance?

Authors:  Troy Day; Silvie Huijben; Andrew F Read
Journal:  Trends Microbiol       Date:  2015-02-11       Impact factor: 17.079

5.  A multi-scale approach to designing therapeutics for tuberculosis.

Authors:  Jennifer J Linderman; Nicholas A Cilfone; Elsje Pienaar; Chang Gong; Denise E Kirschner
Journal:  Integr Biol (Camb)       Date:  2015-04-30       Impact factor: 2.192

Review 6.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

Review 7.  Persistence: a copacetic and parsimonious hypothesis for the existence of non-inherited resistance to antibiotics.

Authors:  Bruce R Levin; Jeniffer Concepción-Acevedo; Klas I Udekwu
Journal:  Curr Opin Microbiol       Date:  2014-08-02       Impact factor: 7.934

8.  A model-guided analysis and perspective on the evolution and epidemiology of antibiotic resistance and its future.

Authors:  Bruce R Levin; Fernando Baquero; Pål J Johnsen
Journal:  Curr Opin Microbiol       Date:  2014-07-11       Impact factor: 7.934

9.  Estimating treatment prolongation for persistent infections.

Authors:  Antal Martinecz; Pia Abel Zur Wiesch
Journal:  Pathog Dis       Date:  2018-08-01       Impact factor: 3.166

10.  ClassTR: Classifying Within-Host Heterogeneity Based on Tandem Repeats with Application to Mycobacterium tuberculosis Infections.

Authors:  Leonid Chindelevitch; Caroline Colijn; Prashini Moodley; Douglas Wilson; Ted Cohen
Journal:  PLoS Comput Biol       Date:  2016-02-01       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.